Trial intelligence / Profile preview

Phase 2 taletrectinib in ROS1-positive advanced NSCLC and other solid tumors

2021-003091-14Phase 2Active

Sponsor

AnHeart Therapeutics

Start

Feb 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1